TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC)

Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

(2023) L.E. Hendriks et al.   ANNALS OF ONCOLOGY

Drug-induced interstitial lung disease during cancer therapies: expert opinion on diagnosis and treatment

(2022) P. Conte et al.   ESMO Open

Comprehensive Genome Profiling in Patients With Metastatic Non–Small Cell Lung Cancer: The Precision Medicine Phase II Randomized SAFIR02-Lung Trial

(2022) Fabrice Barlesi et al.   CLINICAL CANCER RESEARCH

Pooled analysis of drug-related interstitial lung disease and/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies

(2022) C.A. Powell et al.   ESMO Open

1188TiP ORCHARD platform study: Osimertinib + datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib

(2022) J. De Langen et al.   ANNALS OF ONCOLOGY

83P Patterns of trophoblast cell surface antigen 2 (TROP2) and epithelial cell adhesion molecule (EPCAM) expression in human tumors: A tissue microarray study on 14,766 tumors

(2022) D. Dum et al.   ANNALS OF ONCOLOGY

974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC)

(2022) S. Novello et al.   ANNALS OF ONCOLOGY

Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer

(2022) Hope S. Rugo et al.   npj Breast Cancer

Antibody-drug conjugates targeting Trop-2: Clinical developments in early breast cancer therapy

(2022) Jae Ho Jeong et al.   BREAST

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

(2021) Hyuna Sung et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Antibody–drug conjugates in solid tumors: a look into novel targets

(2021) Carmen Criscitiello et al.   Journal of Hematology & Oncology

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non–Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50%

(2021) Martin Reck et al.   JOURNAL OF CLINICAL ONCOLOGY

Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial

(2021) A. Bardia et al.   ANNALS OF ONCOLOGY

LBA49 Efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC) and actionable genomic alterations (AGAs): Preliminary results from the phase I TROPION-PanTumor01 study

(2021) E.B. Garon et al.   ANNALS OF ONCOLOGY

A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).

(2021) Kiyotaka Yoh et al.   JOURNAL OF CLINICAL ONCOLOGY

TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).

(2021) Funda Meric-Bernstam et al.   JOURNAL OF CLINICAL ONCOLOGY

Datopotamab deruxtecan (Dato-DXd), a novel TROP2-directed antibody-drug conjugate, demonstrates potent antitumor activity by efficient drug delivery to tumor cells

(2021) Daisuke Okajima et al.   MOLECULAR CANCER THERAPEUTICS

Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

(2021) James T. Coates et al.   Cancer Discovery

MA03.02 TROPION-PanTumor01: Updated Results From the NSCLC Cohort of the Phase 1 Study of Datopotamab Deruxtecan in Solid Tumors

(2021) E. Garon et al.   Journal of Thoracic Oncology

Antibody-drug conjugates: A promising novel therapeutic approach in lung cancer

(2021) Aakash Desai et al.   LUNG CANCER

Novel ADCs and Strategies to Overcome Resistance to Anti-HER2 ADCs

(2021) Elena Díaz-Rodríguez et al.   Cancers

Clinical impact of TROP2 in non‐small lung cancers and its correlation with abnormal p53 nuclear accumulation

(2020) Remi Mito et al.   PATHOLOGY INTERNATIONAL

TROPiCS–03: A phase II open-label study of sacituzumab govitecan (SG) in patients with metastatic solid tumors.

(2020) Ashish Saxena et al.   JOURNAL OF CLINICAL ONCOLOGY

57P Functional inactivation of E-cadherin by Trop-2 drives cancer metastasis

(2020) S. Alberti et al.   ANNALS OF ONCOLOGY

Interstitial pneumonitis related to trastuzumab deruxtecan, a HER2‐targeting antibody drug conjugate, in monkeys

(2020) Kazuyoshi Kumagai et al.   CANCER SCIENCE

Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time

(2020) Emma C. Hulshof et al.   EUROPEAN JOURNAL OF CANCER

Acquired Resistance to Antibody-Drug Conjugates

(2019) Denis Collins et al.   Cancers

Antibody–drug conjugates for cancer

(2019) Cindy H Chau et al.   LANCET

LBA55Initial results from TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients (Pts) with metastatic urothelial cancer (mUC) after failure of platinum-based regimens (PLT) or immunotherapy

(2019) S T Tagawa et al.   ANNALS OF ONCOLOGY

A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors

(2018) Gentry T. King et al.   INVESTIGATIONAL NEW DRUGS

Molecular Testing Guideline for the Selection of Patients With Lung Cancer for Treatment With Targeted Tyrosine Kinase Inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update

(2018) Gregory P. Kalemkerian et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab plus Chemotherapy in Lung Cancer

(2018)   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

(2018) Luis Paz-Ares et al.   NEW ENGLAND JOURNAL OF MEDICINE

Therapy of Advanced Non–Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan

(2017) Rebecca Suk Heist et al.   JOURNAL OF CLINICAL ONCOLOGY

Strategies and challenges for the next generation of antibody–drug conjugates

(2017) Alain Beck et al.   NATURE REVIEWS DRUG DISCOVERY

Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes

(2017) Kentaro Inamura et al.   Oncotarget

First-in-Human Trial of a Novel Anti-Trop-2 Antibody-SN-38 Conjugate, Sacituzumab Govitecan, for the Treatment of Diverse Metastatic Solid Tumors

(2015) A. N. Starodub et al.   CLINICAL CANCER RESEARCH

T-cell redirected killing and cure of pancreatic and gastric cancer xenografts by targeting Trop-2.

(2015) David M. Goldenberg et al.   JOURNAL OF CLINICAL ONCOLOGY

Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC)*

(2015) David M. Goldenberg et al.   Oncotarget

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs

(2014) Mark G. Kris et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Trastuzumab emtansine (T-DM1) for HER2-positive breast cancer

(2013) Baris Boyraz et al.   CURRENT MEDICAL RESEARCH AND OPINION

Biochemical and preliminary X-ray characterization of the tumor-associated calcium signal transducer 2 (Trop2) ectodomain

(2013) Tilen Vidmar et al.   PROTEIN EXPRESSION AND PURIFICATION

Expression and clinical significance of the Trop-2 gene in advanced non-small cell lung carcinoma

(2013) AIGUI JIANG et al.   Oncology Letters

The Trop-2 signalling network in cancer growth

(2012) E Guerra et al.   ONCOGENE

Significance of EpCAM and TROP2 expression in non-small cell lung cancer

(2012) Min Pak et al.   World Journal of Surgical Oncology